Groundbreaking Lymphoma Treatments May Bring Great Change
Who is Aliqopa for?
Aliqopa is made for patients suffering from follicular lymphoma. Follicular lymphoma is a slow growing type of non-Hodgkin lymphoma that is found in many patients. Aliqopa is a kinase inhibitor (kinase is comprised of enzymes that catalyze the transfer of phosphate groups from phosphate donating molecules to specific cell pieces), which helps block enzymes that promote cancer cell growth. Aliqopa received the FDA's Accelerated Approval, which enables the FDA to approve drugs for serious conditions to fulfill an unmet medical need using clinical trial data that is meant to predict clinical benefits granted to patients.
